BridgeBio Pharma (NASDAQ:BBIO) Short Interest Update

Kohlberg Kravis Roberts & Co. L.P. acquired a new position in shares of BridgeBio Pharma during the 2nd quarter worth approximately $995,211,000.

BridgeBio Pharma logoBridgeBio Pharma (NASDAQ:BBIO) was the target of a large decline in short interest in October. As of October 15th, there was short interest totalling 3,170,000 shares, a decline of 7.3% from the September 15th total of 3,420,000 shares. Based on an average daily volume of 255,600 shares, the short-interest ratio is currently 12.4 days. Currently, 4.9% of the company’s stock are sold short.

BBIO stock opened at $22.61 on Friday. BridgeBio Pharma has a 1-year low of $17.61 and a 1-year high of $32.94. The business’s 50 day simple moving average is $21.17.

Several hedge funds have recently bought and sold shares of the stock. Kohlberg Kravis Roberts & Co. L.P. acquired a new position in shares of BridgeBio Pharma during the 2nd quarter worth approximately $995,211,000. Viking Global Investors LP acquired a new position in shares of BridgeBio Pharma during the 2nd quarter worth approximately $717,968,000. American International Group Inc. acquired a new position in shares of BridgeBio Pharma during the 2nd quarter worth approximately $181,569,000. Perceptive Advisors LLC acquired a new position in shares of BridgeBio Pharma during the 2nd quarter worth approximately $180,868,000. Finally, Aisling Capital Management LP acquired a new position in shares of BridgeBio Pharma during the 2nd quarter worth approximately $103,449,000. 85.32% of the stock is currently owned by institutional investors and hedge funds.

Several equities analysts have recently weighed in on the company. Piper Jaffray Companies dropped coverage on BridgeBio Pharma in a report on Friday, October 18th. JPMorgan Chase & Co. began coverage on BridgeBio Pharma in a research report on Monday, July 22nd. They set an “overweight” rating and a $38.00 price target on the stock. BMO Capital Markets began coverage on BridgeBio Pharma in a research report on Monday, July 22nd. They set an “outperform” rating and a $49.00 price target on the stock. Svb Leerink began coverage on BridgeBio Pharma in a research report on Monday, July 22nd. They set an “outperform” rating and a $34.00 price target on the stock. Finally, Raymond James began coverage on BridgeBio Pharma in a research report on Friday, July 26th. They set an “outperform” rating and a $36.00 price target on the stock. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $40.13.

About BridgeBio Pharma

BridgeBio Pharma, Inc finds, develops, and delivers various medicines for genetic diseases. The company has a pipeline of 15 development programs that include product candidates ranging from early discovery to late-stage development in various therapeutic areas, including genetic dermatology, oncology, cardiology, neurology, endocrinology, renal disease, and ophthalmology.

Featured Story: How to track put option volume

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts